{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2676267"],"location":["China"],"study_start_month":["3"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Study on antiangiogenic transformation medicine of advanced colorectal cancer based on APE1 expression","description":"Interventions: Experimental group:Endostar combined with FOLFOX;Control group:FOLFOX\nPrimary outcome(s): PFS;ORR\nStudy Design: Randomized parallel controlled trial","dates":{"creation":"2018-03-15"},"accession":"2676267","cross_references":{"Chinese Clinical Trial Register":["ChiCTR1800014879"]}}